Abstract
Spontaneous autoantibody responses against tumor-associated antigens have been detected in all types of cancer analyzed so far. Recent studies have shown that cancer-associated autoantibodies can be found in the serum of patients even several years before the clinical diagnosis. Furthermore, they may at least partially reflect the antigenic profile of cancer and the balance of immune cell subsets in the tumor microenvironment. Therefore, cancer associatedautoantibodies represent attractive biomarkers for the development of non-invasive serological tests for the diagnosis or early detection of cancer, prognosis of survival and prediction of the clinical benefit of immunotherapy. Still, the frequency of responses against each particular antigen is generally low and the autoantibody repertoire is highly heterogeneous and overlapping with that elicited by viral infections and autoimmune disorders, hence precluding the clinical use of single autoantibody biomarkers. This can, however, be overcome by analyzing the autoantibody responses to multiple antigens simultaneously. In this review, we discuss the diagnostic relevance of the recently identified cancer-associated autoantibody signatures and the challenges in the development of clinically applicable biomarker assays. In addition, the putative functional role and the significance of IgG subclasses in the anti-tumor immune response and their prognostic value are discussed.
Keywords: Autoantibodies, B cells, biomarkers, early detection of cancer, proteomics, tumor antigens.
Current Cancer Therapy Reviews
Title:Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update
Volume: 9 Issue: 4
Author(s): Irena Meistere, Zane Kalnina, Karina Silina and Aija Line
Affiliation:
Keywords: Autoantibodies, B cells, biomarkers, early detection of cancer, proteomics, tumor antigens.
Abstract: Spontaneous autoantibody responses against tumor-associated antigens have been detected in all types of cancer analyzed so far. Recent studies have shown that cancer-associated autoantibodies can be found in the serum of patients even several years before the clinical diagnosis. Furthermore, they may at least partially reflect the antigenic profile of cancer and the balance of immune cell subsets in the tumor microenvironment. Therefore, cancer associatedautoantibodies represent attractive biomarkers for the development of non-invasive serological tests for the diagnosis or early detection of cancer, prognosis of survival and prediction of the clinical benefit of immunotherapy. Still, the frequency of responses against each particular antigen is generally low and the autoantibody repertoire is highly heterogeneous and overlapping with that elicited by viral infections and autoimmune disorders, hence precluding the clinical use of single autoantibody biomarkers. This can, however, be overcome by analyzing the autoantibody responses to multiple antigens simultaneously. In this review, we discuss the diagnostic relevance of the recently identified cancer-associated autoantibody signatures and the challenges in the development of clinically applicable biomarker assays. In addition, the putative functional role and the significance of IgG subclasses in the anti-tumor immune response and their prognostic value are discussed.
Export Options
About this article
Cite this article as:
Meistere Irena, Kalnina Zane, Silina Karina and Line Aija, Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update, Current Cancer Therapy Reviews 2013; 9 (4) . https://dx.doi.org/10.2174/157339470904140418093612
DOI https://dx.doi.org/10.2174/157339470904140418093612 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
CNS & Neurological Disorders - Drug Targets A Proteomics Study of the Subacute Toxicity of Rat Brain after Long- Term Exposure of <i>Gelsemium elegans</i>
Current Molecular Pharmacology Area, Age and Gender Dependence of the Nucleoside System in the Brain: a Review of Current Literature
Current Topics in Medicinal Chemistry PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation
Current Pharmaceutical Design Nucleo-Cytoplasmic Transport of Proteins as a Target for Therapeutic Drugs
Current Medicinal Chemistry Multimodality Imaging of CXCR4 in Cancer: Current Status towards Clinical Translation
Current Molecular Medicine Biosafety of Recombinant Adeno-associated Virus Vectors
Current Gene Therapy Unique Biology of Mcl-1: Therapeutic Opportunities in Cancer
Current Molecular Medicine Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy
Current Pharmaceutical Design Editorial (Thematic Issue: Signalling Pathways in Anti-cancer Drug Resistance)
Current Medicinal Chemistry Antioxidant Potential of Solvent Partitioned Extraction from Aqueous Extract of Gracilaria Tenuistipitata
Current Organic Chemistry Tumor Angiogenesis: A Potential Target In Cancer Control by Phytochemicals
Current Cancer Drug Targets Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Thioethers: An Overview
Current Drug Targets Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to Overcome Drug Resistance in Cancer
Current Drug Targets Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry Preparation and Primary Bioevaluation of 99mTc-labeled-1-thio-β-D-Glucose as Melanoma Targeting Agent
Current Radiopharmaceuticals